PL2480671T3 - Proces produkcji cząsteczek zawierających specjalne struktury glikanowe - Google Patents
Proces produkcji cząsteczek zawierających specjalne struktury glikanoweInfo
- Publication number
- PL2480671T3 PL2480671T3 PL10757168T PL10757168T PL2480671T3 PL 2480671 T3 PL2480671 T3 PL 2480671T3 PL 10757168 T PL10757168 T PL 10757168T PL 10757168 T PL10757168 T PL 10757168T PL 2480671 T3 PL2480671 T3 PL 2480671T3
- Authority
- PL
- Poland
- Prior art keywords
- molecules containing
- glycan structures
- producing molecules
- containing specialized
- specialized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24462409P | 2009-09-22 | 2009-09-22 | |
| PCT/EP2010/005772 WO2011035884A1 (en) | 2009-09-22 | 2010-09-21 | Process for producing molecules containing specialized glycan structures |
| EP10757168.9A EP2480671B8 (en) | 2009-09-22 | 2010-09-21 | Process for producing molecules containing specialized glycan structures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2480671T3 true PL2480671T3 (pl) | 2015-12-31 |
Family
ID=43127046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10757168T PL2480671T3 (pl) | 2009-09-22 | 2010-09-21 | Proces produkcji cząsteczek zawierających specjalne struktury glikanowe |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8642292B2 (pl) |
| EP (1) | EP2480671B8 (pl) |
| JP (1) | JP5746183B2 (pl) |
| KR (1) | KR101545914B1 (pl) |
| CN (1) | CN102648280B (pl) |
| AU (1) | AU2010297580B2 (pl) |
| BR (1) | BR112012006388B1 (pl) |
| CA (1) | CA2773240C (pl) |
| EA (1) | EA026336B1 (pl) |
| IL (1) | IL218485A (pl) |
| MX (1) | MX2012003404A (pl) |
| MY (1) | MY160680A (pl) |
| PL (1) | PL2480671T3 (pl) |
| SG (1) | SG178925A1 (pl) |
| WO (1) | WO2011035884A1 (pl) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2322221E (pt) | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| HUE027332T2 (en) | 2008-08-05 | 2016-09-28 | Toray Industries | Cancer Detection Method |
| PT2532743E (pt) | 2010-02-04 | 2015-08-04 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro |
| MX2012008991A (es) | 2010-02-04 | 2012-09-07 | Toray Industries | Medicamento para tratar y/o prevenir el cancer. |
| EP2532365B1 (en) | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US9765158B2 (en) | 2011-05-31 | 2017-09-19 | Probiogen Ag | Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders |
| KR101968498B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| US9796775B2 (en) | 2011-08-04 | 2017-10-24 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
| KR101980557B1 (ko) | 2011-08-04 | 2019-05-21 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| JP6003650B2 (ja) | 2011-08-04 | 2016-10-05 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| JP6065591B2 (ja) | 2011-08-04 | 2017-01-25 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| PT3351630T (pt) | 2011-08-04 | 2019-12-30 | Toray Industries | Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro |
| EP2740798B1 (en) | 2011-08-04 | 2016-12-07 | Toray Industries, Inc. | Cancer treatment and/or prevention drug composition |
| AU2013223137B2 (en) | 2012-02-21 | 2017-10-19 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| CA2864869C (en) | 2012-02-21 | 2021-10-19 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| RU2633505C2 (ru) | 2012-02-21 | 2017-10-12 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| MX360208B (es) | 2012-02-21 | 2018-10-24 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| JP6107655B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 胆嚢癌の治療及び／又は予防用医薬組成物 |
| PL2832365T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby |
| CN104471404B (zh) | 2012-07-19 | 2017-03-01 | 东丽株式会社 | 癌的检测方法 |
| HUE043162T2 (hu) | 2012-07-19 | 2019-08-28 | Toray Industries | Eljárás rák detektálására |
| JP6447130B2 (ja) * | 2013-08-09 | 2019-01-09 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2015057393A1 (en) * | 2013-10-01 | 2015-04-23 | University Of Wyoming | Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production recombinant glycoproteins |
| HUE047283T2 (hu) | 2013-12-09 | 2020-04-28 | Allakos Inc | Anti-SIGLEC-8 antitestek és eljárások az alkalmazásukra |
| JP6825909B2 (ja) | 2014-02-28 | 2021-02-03 | アラコス インコーポレイテッド | シグレック−８関連疾患を処置するための方法および組成物 |
| MX2016013449A (es) * | 2014-04-18 | 2017-05-04 | Glycotope Gmbh | Hiperestimulacion ovarica controlada con la hormona estimuladora folicular humana recombinante mejorada. |
| WO2016007506A1 (en) * | 2014-07-07 | 2016-01-14 | Targazyme, Inc. | Manufacture and cryopreservation of fucosylated cells for therapeutic use |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| WO2017062496A2 (en) * | 2015-10-05 | 2017-04-13 | University Of Virginia Patent Foundation | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| WO2017181034A1 (en) | 2016-04-14 | 2017-10-19 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody |
| CN109154604B (zh) * | 2016-04-24 | 2023-07-21 | 沃特世科技公司 | 用于对用两亲强碱性部分改性的聚糖进行分析的带电表面反相色谱材料方法 |
| BR112019008335A2 (pt) | 2016-10-28 | 2020-01-28 | Toray Industries | conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2018160536A1 (en) | 2017-02-28 | 2018-09-07 | Bristol-Myers Squibb Company | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| MX2019013137A (es) | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar enfermedades oculares alergicas. |
| CN110997723B (zh) | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| AU2018280868A1 (en) | 2017-06-08 | 2020-01-02 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CN111032693B (zh) | 2017-08-16 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| US11236173B2 (en) | 2017-08-16 | 2022-02-01 | Black Belt Therapeutics Limited | CD38 antibody |
| KR20200131861A (ko) | 2018-03-13 | 2020-11-24 | 터스크 테라퓨틱스 리미티드 | 종양 특이적 세포 고갈에 대한 항-cd25 |
| AU2019236865A1 (en) | 2018-03-23 | 2020-10-01 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| WO2019189780A1 (ja) | 2018-03-30 | 2019-10-03 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP7292377B2 (ja) * | 2018-08-29 | 2023-06-16 | ユナイテッド バイオファーマ インコーポレイテッド | アフコシル化抗体およびその製造法 |
| KR20210153100A (ko) | 2019-04-18 | 2021-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 낮은 pH에서의 결합에 대한 증진된 특이성을 갖는 이필리무맙 변이체 |
| EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| US20230075422A1 (en) | 2019-12-20 | 2023-03-09 | Bristol-Myers Squibb Company | Use of fucosylation inhibitor for producing afucosylated antibody |
| EP4119157A4 (en) | 2020-03-12 | 2024-03-27 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2021182572A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20220152309A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| BR112022018161A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| US20230257472A1 (en) | 2020-06-30 | 2023-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd70 antibody and application thereof |
| KR20230050389A (ko) | 2020-08-13 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-2를 관심 표적 세포로 재지시하는 방법 |
| WO2022098952A1 (en) | 2020-11-06 | 2022-05-12 | Bristol-Myers Squibb Company | Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy |
| PE20231386A1 (es) | 2020-12-18 | 2023-09-12 | Lamkap Bio Beta Ltd | Anticuerpos biespecificos contra ceacam5 y cd47 |
| IL305690A (en) | 2021-03-18 | 2023-11-01 | Medimmune Ltd | A therapeutic binding molecule that binds to CCR9 |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| AU2022296193A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3225422A1 (en) | 2021-06-23 | 2022-12-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4372001A1 (en) | 2021-07-14 | 2024-05-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof |
| CN117693363A (zh) | 2021-07-27 | 2024-03-12 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2023008461A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| TW202319400A (zh) | 2021-09-02 | 2023-05-16 | 瑞士商赫孚孟拉羅股份公司 | 用於治療aml之抗體 |
| JPWO2023033129A1 (pl) | 2021-09-03 | 2023-03-09 | ||
| WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
| WO2023245106A1 (en) | 2022-06-16 | 2023-12-21 | Abbvie Biotherapeutics Inc. | Anti-cd19 antibody drug conjugates |
| WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
| WO2024031032A1 (en) | 2022-08-05 | 2024-02-08 | Bristol-Myers Squibb Company | Anti-ctla-4 antibodies for treatment of kras mutant cancers |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| ES2651952T3 (es) * | 2000-10-06 | 2018-01-30 | Kyowa Hakko Kirin Co., Ltd. | Células que producen unas composiciones de anticuerpo |
| CA2923247A1 (en) * | 2002-03-19 | 2003-09-25 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
| EP2228445A1 (en) * | 2003-06-18 | 2010-09-15 | Chugai Seiyaku Kabushiki Kaisha | Fucose Transporter |
| US20060223147A1 (en) | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
| JPWO2006067847A1 (ja) | 2004-12-22 | 2008-06-12 | 中外製薬株式会社 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
| CA2608818A1 (en) * | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
-
2010
- 2010-09-21 CA CA2773240A patent/CA2773240C/en active Active
- 2010-09-21 BR BR112012006388-0A patent/BR112012006388B1/pt active IP Right Grant
- 2010-09-21 US US13/496,997 patent/US8642292B2/en active Active
- 2010-09-21 EA EA201200516A patent/EA026336B1/ru not_active IP Right Cessation
- 2010-09-21 WO PCT/EP2010/005772 patent/WO2011035884A1/en active Application Filing
- 2010-09-21 EP EP10757168.9A patent/EP2480671B8/en active Active
- 2010-09-21 MX MX2012003404A patent/MX2012003404A/es active IP Right Grant
- 2010-09-21 SG SG2012014346A patent/SG178925A1/en unknown
- 2010-09-21 AU AU2010297580A patent/AU2010297580B2/en active Active
- 2010-09-21 JP JP2012530159A patent/JP5746183B2/ja active Active
- 2010-09-21 PL PL10757168T patent/PL2480671T3/pl unknown
- 2010-09-21 MY MYPI2012001308A patent/MY160680A/en unknown
- 2010-09-21 CN CN201080042140.5A patent/CN102648280B/zh active Active
- 2010-09-21 KR KR1020127007260A patent/KR101545914B1/ko active IP Right Grant
-
2012
- 2012-03-05 IL IL218485A patent/IL218485A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010297580A1 (en) | 2012-03-29 |
| CA2773240A1 (en) | 2011-03-31 |
| BR112012006388B1 (pt) | 2022-01-04 |
| EP2480671B8 (en) | 2015-10-28 |
| KR101545914B1 (ko) | 2015-08-20 |
| US20120214975A1 (en) | 2012-08-23 |
| WO2011035884A1 (en) | 2011-03-31 |
| EA026336B1 (ru) | 2017-03-31 |
| EP2480671B1 (en) | 2015-09-02 |
| MX2012003404A (es) | 2012-09-12 |
| JP2013505028A (ja) | 2013-02-14 |
| EA201200516A1 (ru) | 2012-10-30 |
| IL218485A0 (en) | 2012-04-30 |
| MY160680A (en) | 2017-03-15 |
| BR112012006388A2 (pt) | 2015-09-08 |
| IL218485A (en) | 2017-03-30 |
| US8642292B2 (en) | 2014-02-04 |
| SG178925A1 (en) | 2012-04-27 |
| JP5746183B2 (ja) | 2015-07-08 |
| CA2773240C (en) | 2015-11-10 |
| EP2480671A1 (en) | 2012-08-01 |
| AU2010297580B2 (en) | 2014-07-31 |
| CN102648280B (zh) | 2014-10-08 |
| CN102648280A (zh) | 2012-08-22 |
| KR20120090981A (ko) | 2012-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL218485A0 (en) | Process for producing molecules containing specialized glycan structures | |
| EP2424567A4 (en) | METHOD FOR PRODUCING HETEROMULTIMER MOLECULES | |
| EP2325153A4 (en) | PROCESS FOR PREPARING ALUMINUM DIAMOND COMPOUND | |
| PT2913337T (pt) | Processo para a produção de sofosbuvir | |
| EP2271636A4 (en) | METHOD FOR PRODUCING DIANEHYDRO SUGAR | |
| SI2414435T1 (sl) | Postopek za proizvodnjo nanovlaknastih celuloznih gelov | |
| GB2474310B (en) | Process for the production of sucrose-6-ester | |
| ZA201109287B (en) | Process for producing polydienes | |
| PL2462088T3 (pl) | Sposób wytwarzania metanu | |
| EP2404985A4 (en) | PROCESS FOR PRODUCING LIPID | |
| EP2292579A4 (en) | PROCESS FOR THE PRODUCTION OF HALOGENATED FLUOROETHERS | |
| EP2330184A4 (en) | METHOD FOR PRODUCING A USEFUL SUBSTANCE | |
| EP2351724A4 (en) | PROCESS FOR PRODUCING p-DICHLOROBENZENE | |
| GB2457820B (en) | Production process | |
| HU0800474D0 (en) | Process for producing ethisterone | |
| EP2487150A4 (en) | PROCESS FOR PRODUCING 2 ALKYLCYCLOALCANONE | |
| EP2221294A4 (en) | PROCESS FOR PREPARING N-CARBAMOYL-TERT.-LEUCIN | |
| IL215692A0 (en) | Process for producing 2-halogeno-6-substituted-4- trifluoromethylpyridine | |
| EP2251329A4 (en) | PROCESS FOR THE PRODUCTION OF 3-AMINO-2-CHLORO-6-TRIFLUOROMETHYLPYRIDINE | |
| IL210133A0 (en) | Process for production of mandelonitrile compound | |
| IL217495A0 (en) | Process for producing thiabenzulene-propionic acid deivative | |
| EP2400024A4 (en) | METHOD FOR PRODUCING A USEFUL SUBSTANCE | |
| HUP0900795A2 (en) | Process for producing prasurgel | |
| EP2327685A4 (en) | PROCESS FOR PRODUCTION OF ACID -AMINATED -TRIFLUOROMETHYL- -SUBSTITUTED | |
| GB0802224D0 (en) | Process for the production of vaccine components |